30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

3Q13 Revenue: Integra LifeSciences

$80.4MM, -2%

  • U.S. Extremities $33.5MM, +2% (Hardware +10%)
  • U.S. Spine & Other $46.9MM, -5%

Extremities includes products serving the skin and wound repair markets ~60% soft tissue/40% metal)


  • Increasing orthobiologic sales offset some decline in spine
  • Commenced limited launch of Titan reverse shoulder and U.S. release of Proximal Humeral Fracture Plate (latter in 4Q)
  • Bringing on dedicated distributors to support 1Q14 full-market release of Titan
  • In 4Q, received FDA 510(k) clearance for the Integra Hollywood NanoMetalene Interbody Device used primarily in Transforaminal Lumbar Interbody Fusion; controlled launch to begin by year-end
  • In 4Q, announced plans to close 2 manufacturing facilities and discontinue certain product lines in segments including Extremities, Instruments, Neurosurgery, International and U.S. Spine and Other